Welcome to our dedicated page for azrx news (Ticker: azrx), a resource for investors and traders seeking the latest updates and insights on azrx stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect azrx's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of azrx's position in the market.
AzurRx BioPharma, Inc. (NASDAQ: AZRX) is set to present at the Maxim Group Emerging Growth Virtual Conference from March 17 to March 18, 2021. CEO James Sapirstein will provide insights into the company's business and clinical programs, highlighting key milestones for 2021. Registered attendees will have access to a pre-recorded presentation and can participate in one-on-one virtual meetings with the management team. AzurRx specializes in targeted therapies for gastrointestinal diseases, currently advancing its lead therapeutic candidate, MS1819, through Phase 2 trials.
AzurRx BioPharma, Inc. (NASDAQ: AZRX) announced a registered direct offering of 7,858,548 shares and warrants to purchase 3,929,274 shares at an effective price of $1.2725 per share. The company expects to raise $10 million, aiming to fund two niclosamide clinical programs in 2021: a Phase 2 trial for COVID-19 GI infections and a Phase 1b/2a trial for immune checkpoint inhibitor-induced colitis. The deal is facilitated by H.C. Wainwright & Co. The expected closing date is around March 10, 2021, pending customary conditions.
AzurRx BioPharma announced that its Chairman and CEO, James Sapirstein, will participate in a panel discussion on SARS-CoV-2 therapeutics during the 33rd Annual Roth Conference from March 15-17, 2021. The session, titled "Therapeutics Against SARS-CoV-2 – Viral Variants Will Not Fade Away," is scheduled for March 15, 2021, from 12:00 to 1:00 p.m. ET. Sapirstein will emphasize the necessity for drug therapies addressing COVID-19, particularly gastrointestinal symptoms. AzurRx is advancing FW-1022 for treating COVID-19 gastrointestinal infections.
AzurRx BioPharma (NASDAQ: AZRX) will showcase its business and clinical programs at the H.C. Wainwright Global Life Sciences Conference from March 9-11, 2021. CEO James Sapirstein will engage in a 'fireside chat' on March 9 at 7:00 a.m. ET, discussing the company’s anticipated milestones for 2021. AzurRx specializes in developing targeted therapies for gastrointestinal diseases, with ongoing clinical programs, including MS1819 for exocrine pancreatic insufficiency. The company aims to connect with investors and pharmaceutical firms during the virtual event.
AzurRx BioPharma (NASDAQ: AZRX) has appointed James Sapirstein as chairman of its board of directors, effective immediately. Sapirstein, also the President and CEO, succeeds Edward J. Borkowski, who remains as the lead independent director. This leadership change comes as the company approaches critical inflection points with its clinical programs, including the lead candidate MS1819 for GI diseases. Borkowski expressed confidence in Sapirstein's ability to guide the company’s strategy, especially following a recent licensing agreement with First Wave Bio.
AzurRx BioPharma (NASDAQ: AZRX) announced that CEO James Sapirstein will present at The Microcap Rodeo Winter Wonderland Conference, taking place virtually from February 16-19, 2021. The presentation is scheduled for February 17, 2021, at 4:30 p.m. ET, where Sapirstein will discuss the company's business, clinical development programs, and anticipated milestones for 2021. Additionally, the management team will hold one-on-one meetings with registered investors. For more information and registration, visit here.
AzurRx BioPharma (NASDAQ: AZRX) announces plans for a Phase 2 clinical trial of FW-1022, a micronized formulation of niclosamide aimed at treating gastrointestinal infections related to COVID-19. The trial, managed by PPD, Inc., is expected to begin in the first half of 2021. AzurRx's FW-1022 targets a significant unmet medical need, as approximately 18% of COVID-19 patients experience GI infection symptoms. Niclosamide's effectiveness is highlighted by its recent identification as a potent SARS-CoV-2 inhibitor, 40 times more potent than remdesivir, indicating potential widespread therapeutic benefits.
AzurRx BioPharma (NASDAQ: AZRX) announced that CEO James Sapirstein will present at the BIO CEO & Investor Digital Conference from February 16-18, 2021. The event will allow registered attendees to access the presentation on demand. Mr. Sapirstein will discuss the company's business, clinical development programs, and upcoming 2021 milestones. Additionally, he and the management team will hold virtual meetings with investors and pharmaceutical companies. AzurRx specializes in therapies for gastrointestinal diseases, focusing on the lead candidate MS1819.
AzurRx BioPharma (NASDAQ: AZRX) has completed patient enrollment in the first cohort of the Phase 2b OPTION 2 extension study for MS1819, aimed at treating exocrine pancreatic insufficiency (EPI) in cystic fibrosis patients. This study, currently dosing patients in the U.S. and Europe, follows earlier trials and seeks to optimize dosage and delivery of MS1819. No serious adverse events have been reported thus far. The company anticipates releasing topline results by the end of Q1 2021, with MS1819 potentially filling a significant market gap valued at over $2 billion globally for non-animal-based therapies.
AzurRx BioPharma (NASDAQ: AZRX) announced the activation of two clinical trial sites in Poland for the Phase 2b OPTION 2 trial, which investigates MS1819 for treating exocrine pancreatic insufficiency (EPI)
